AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
diosmin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 3157 | 520-27-4 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A bioflavonoid that strengthens vascular walls.
|
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2B,ACVRL1,AURKA,AXL,BRAF,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,ERBB2,GRK2,ITK,MAP2K6,MAP3K21,MAPK10,MAPK7,NTRK2,PDK1,PDK2,PDK4,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PIM2,PRKDC,SIK2,STK33,SYK,TEK,TGFBR1,ZAP70 | 35 | |||
| kinase-selectivity-class | AXL,CDK9,CHUK,GRK2,MAP2K6,MAP3K14,PDK1,PIK3CA,PIK3CD,PRKDC,ZAP70 | 11 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
None
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Tubulointerstitial nephritis and uveitis syndrome | 66.77 | 21.98 | 10 | 1539 | 262 | 90626636 |
| Erysipelas | 63.14 | 21.98 | 17 | 1532 | 9035 | 90617863 |
| Myoglobin blood increased | 43.49 | 21.98 | 9 | 1540 | 1543 | 90625355 |
| Hypercapnia | 34.88 | 21.98 | 10 | 1539 | 6667 | 90620231 |
| Delirium | 30.23 | 21.98 | 20 | 1529 | 104339 | 90522559 |
| Activated partial thromboplastin time prolonged | 29.04 | 21.98 | 9 | 1540 | 7816 | 90619082 |
| Hepatic encephalopathy | 24.05 | 21.98 | 9 | 1540 | 13763 | 90613135 |
| Thrombocytopenia | 23.55 | 21.98 | 23 | 1526 | 208702 | 90418196 |
| Drug interaction | 23.21 | 21.98 | 26 | 1523 | 276427 | 90350471 |
| Hepatitis acute | 22.29 | 21.98 | 8 | 1541 | 10879 | 90616019 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Blood lactic acid | 97.08 | 43.34 | 14 | 611 | 332 | 42620378 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Blood lactic acid | 88.48 | 23.01 | 14 | 2140 | 464 | 110586681 |
| Tubulointerstitial nephritis and uveitis syndrome | 61.46 | 23.01 | 10 | 2144 | 396 | 110586749 |
| Erysipelas | 54.63 | 23.01 | 17 | 2137 | 13141 | 110574004 |
| Myoglobin blood increased | 38.09 | 23.01 | 10 | 2144 | 4222 | 110582923 |
| Lentigo maligna | 36.90 | 23.01 | 7 | 2147 | 675 | 110586470 |
| Ventricular tachycardia | 35.54 | 23.01 | 18 | 2136 | 49991 | 110537154 |
| Hypercapnia | 32.41 | 23.01 | 11 | 2143 | 11148 | 110575997 |
| Lower respiratory tract congestion | 23.32 | 23.01 | 7 | 2147 | 4789 | 110582356 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | C05CA03 | CARDIOVASCULAR SYSTEM VASOPROTECTIVES CAPILLARY STABILIZING AGENTS Bioflavonoids |
| ATC | C05CA53 | CARDIOVASCULAR SYSTEM VASOPROTECTIVES CAPILLARY STABILIZING AGENTS Bioflavonoids |
| CHEBI has role | CHEBI:22586 | antioxidant |
| CHEBI has role | CHEBI:35554 | cardiovascular drug |
| CHEBI has role | CHEBI:35842 | antirheumatic drug |
| CHEBI has role | CHEBI:49201 | anti-ulcer drug |
| CHEBI has role | CHEBI:67079 | anti-inflammatory agent |
Related Drugs by ATC class:
C05CA Bioflavonoids 4 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
None
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 6.73 | acidic |
| pKa2 | 10.43 | acidic |
| pKa3 | 12.32 | acidic |
| pKa4 | 13.05 | acidic |
| pKa5 | 13.7 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Lysine-specific histone demethylase 1A | Enzyme | IC50 | 4.99 | CHEMBL | |||||
| Inhibitor of nuclear factor kappa-B kinase subunit beta | Kinase | IC50 | 5.41 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| N0000167025 | NUI |
| D07858 | KEGG_DRUG |
| 4036523 | VANDF |
| C0012498 | UMLSCUI |
| CHEBI:4631 | CHEBI |
| CHEMBL231884 | ChEMBL_ID |
| D004145 | MESH_DESCRIPTOR_UI |
| DB08995 | DRUGBANK_ID |
| 4370 | INN_ID |
| 7QM776WJ5N | UNII |
| 5281613 | PUBCHEM_CID |
| 3489 | RXNORM |
| 005803 | NDDF |
| 126142004 | SNOMEDCT_US |
| 8143001 | SNOMEDCT_US |
| 7QM776WJ5N | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Bruselix Bruising | HUMAN PRESCRIPTION DRUG LABEL | 8 | 59088-003 | TABLET | 200 mg | ORAL | unapproved drug other | 10 sections |